

The IX International Meeting on Cancer Induced Bone Disease

October 28 - October 31, 2009

Doubletree Hotel Crystal City • Arlington, Virginia

Chairman

Gregory R. Mundy, M.D.
Vanderbilt Center for Bone Biology
Nashville, Tennessee

Organizing Committee

Robert Coleman, MBBS, M.D., FRCP
University of Sheffield
Sheffield, United Kingdom

Allan Lipton, M.D.
Milton S. Hershey Medical Center
Hershey, Pennsylvania

Kenneth J. Pienta, M.D.
University of Michigan
Comprehensive Cancer Center
Ann Arbor, Michigan

G. David Roodman, M.D., Ph.D.
University of Pittsburgh
Pittsburgh, Pennsylvania

Robert Vessella, Ph.D.
University of Washington
Medical Center
Seattle, Washington



First Program Announcement

Jointly Organized By



*The Bone and Cancer Foundation is a program of The Paget Foundation
for Paget's Disease of Bone and Related Disorders*

General Information

The Cancer and Bone Society (CABS) and the Bone and Cancer Foundation (BCF) invite you to attend the **IX International Meeting on Cancer and Bone Disease**, taking place October 28- 31, 2009 at the Doubletree Hotel Crystal City in Arlington, Virginia. The conference will bring together leading clinicians and researchers with expertise in bone metastases and bone and cancer cell biology.

The conference will include:

- presentations by internationally known experts
- oral presentations by authors selected from submitted abstracts
- poster sessions

Objectives

Upon completion of this continuing medical education activity, the participant should be able to:

- Understand the importance of both the physical and cellular bone microenvironment and the hematopoietic stem cell niche in supporting the growth of metastatic cancer cells
- Understand the role of cancer stem cells and hematopoietic stem cells in the metastatic process
- Understand the current state of the field of genomics and proteomics as applied to bone metastasis
- Learn about the efficacy of new therapeutic agents and imaging techniques for bone cancers and bone metastasis.

Intended Audience

This continuing medical education program is designed for medical professionals with an interest in cancer and the complications associated with metastasis to the skeleton. Attendees would include but not be limited to basic scientists and clinicians including oncologists, urologists, hematologists, endocrinologists, orthopedic surgeons, nurses and other allied health professionals. Special effort will be made to include young investigators.

CME Accreditation

This activity will be planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). Final CME provider and total credit hours will be provided at a later date.

Welcome and Overview

MECHANISMS OF BONE METASTASIS

Gregory R. Mundy, Chairman
Vanderbilt Center for Bone Biology
Nashville, TN

NEW INSIGHTS INTO BONE METASTASIS

CANCER STEM CELLS

REGULATION OF CANCER STEM CELLS BY STEM CELL NICHE

Laura Calvi, M.D.
University of Rochester School of Medicine
Rochester, NY

CANCER STEM CELLS IN MULTIPLE MYELOMA

William Matsui, M.D.
Johns Hopkins University
Baltimore, MD

EFFECTS OF HEMATOPOIETIC CELLS AND CANCER

THE ROLE OF HEMATOPOIETIC PROGENITORS IN BONE METASTASIS

Russell Taichman, D.M.D., D.M.Sc.
University of Michigan School of Dentistry
Ann Arbor, MI

IMMUNE CELLS IN THE MYELOMA MICROENVIRONMENT

Madhav Dhodapkar, M.D.
Yale University
New Haven, CT

CANCER ASSOCIATED FIBROBLASTS

INTERACTIVE BIOLOGY IN STROMAL RESPONSES: A DRIVING FORCE IN CARCINOGENESIS

Simon Hayward, Ph.D.
Vanderbilt University Medical Center
Nashville, TN

CO-EVOLUTION OF REACTIVE STROMA AND CANCER PROGRESSION

David R. Rowley, Ph.D.
Baylor College of Medicine
Houston, TX

THE MYELOMA MICROENVIRONMENT

Claire Edwards, Ph.D.
Vanderbilt Center for Bone Biology
Nashville, TN

PRELIMINARY PROGRAM

TGF-B AND METASTASIS

PARACRINE SIGNALING IN BREAST CANCER BONE METASTASIS MEDIATED BY TGF-B AND MATRIX METALLOPROTEASES

Yibin Kang, Ph.D.
Princeton University
Princeton, NJ

TUMOR ANGIOGENESIS

MYELOMA CELLS-OSTEOCLAST INTERACTIONS PROMOTE ANGIOGENESIS

Toshio Matsumoto, M.D.
University of Tokushima
Tokushima, Japan

IMAGING AND PROTEOMICS OF BONE METASTASIS

NEW APPROACHES TO IMAGING BONE METASTASIS

Gabri van der Pluijm, M.D.
Leiden University Medical Center
Leiden, The Netherlands

MATHEMATICAL MODELING AND CARCINOGENESIS

INTEGRATIVE MATHEMATICAL MODELS OF MICROENVIRONMENT DRIVEN TUMOR INVASION

Alexander R.A. Anderson, Ph.D.
H. Lee Moffitt Cancer Center & Research Institute
Tampa, FL

CLINICAL APPROACHES TO METASTATIC BONE DISEASE

PREVENTION OF BONE METASTASIS

ARE BISPHOSPHONATES ANTI-CANCER DRUGS?

Robert Coleman, M.D.
University of Sheffield
Sheffield, United Kingdom

POTENTIAL MECHANISMS OF BISPHOSPHONATES AS ANTI-CANCER DRUGS

Mike Rogers, Ph.D.
University of Aberdeen
Aberdeen, Scotland

INTERFERON GAMMA FOR PREVENTION OF BONE METASTASIS

Katherine Weilbaecher, M.D.
Washington University School of Medicine
St. Louis, MO

NEW ANTI-RESORPTIVE AGENTS

EFFICACY OF NEW ANTI-RESORPTIVES FOR BONE METASTASIS

Allan Lipton, M.D.
Milton S. Hershey Medical Center
Hershey, PA

BIOCHEMICAL MARKERS OF BONE METASTASIS IN METASTATIC BONE DISEASE

Patrick Garnero, Ph.D., D.Sc.
INSERM Unit 664
Lyon, France

ANABOLIC AGENTS FOR OSTEOLYTIC DISEASE

SCLEROSTIN AS AN ANABOLIC AGENT FOR BONE METASTASIS

Clemens W.G.M. Lowik, M.D.
Leiden University Medical Center
Leiden, The Netherlands

TARGETING DKK1 IN MYELOMA

John D. Shaughnessy, Ph.D.
Myeloma Institute for Research and Therapy
Little Rock, AR

MATHEMATICAL MODELING AND DOSE DENSE CHEMOTHERAPY

MATHEMATICAL MODELING AND CARCINOGENESIS

Larry Norton, M.D.
Memorial Sloan-Kettering Cancer Center
New York, NY

BIOLOGY AND TREATMENT OF PROSTATE CANCER BONE METASTASIS

CLINICAL APPROACHES TO PATIENTS WITH PROSTATE CANCER AND BONE METASTASIS

Kenneth J. Pienta, M.D.
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

THE ROLE OF CIRCULATING PROSTATE CANCER CELLS IN BONE METASTASIS

Robert L. Vessella, Ph.D.
University of Washington School of Medicine
Seattle, WA

MOLECULAR MECHANISMS OF BONE METASTASIS IN PROSTATE CANCER

Gregory A. Clines, M.D.
University of Virginia Cancer Center
Charlottesville, VA

Disclaimer

All parties will make reasonable efforts to present educational subject matter in a scientific, balanced and unbiased way. However, participants must always use their own judgment and professional opinion when considering future application of this information, particularly as it may relate to patient diagnostic or treatment decisions.

The Cancer and Bone Society (CABS) and the Bone and Cancer Foundation (BCF) do not endorse or promote any commercial product that may be discussed in this activity.

CALL FOR ABSTRACTS

PREVIOUS DEADLINE: JUNE 1, 2009

*Abstract Deadline
Extended!*

New Deadline: June 12, 2009

The organizers encourage submission of abstracts relevant to current topics in the area of cancer and bone. After peer review, all accepted abstracts will be eligible for poster presentation. Selected high scoring abstracts will be considered for oral presentation. In addition, several travel grants for young investigators will be awarded to abstracts with high merit.

ABSTRACT CATEGORIES INCLUDE:

- Basic Mechanisms
- Therapeutic Approaches
- Clinical Studies

Submit your abstract on line at
www.cancerandbonesociety.org
and click on the meetings tab.

Poster Preparation: Posters will be displayed on typical 6ft. (wide) x 4ft. (tall) standard poster boards. Authors are expected to be present at the conference or have at least one representative to man the poster during the designated poster times.

Registration Fee **\$450 (USD)**

Resident/Fellows/Allied Health\$250 (USD)

Registration fee includes meeting materials, lunch, and refreshment breaks each day.

Hotel & Travel Information

Doubletree Hotel Crystal City is near Washington DC and just minutes away from the Reagan National Airport. Located across the Potomac River from the nation's capital, the hotel offers guest room comfort in the beautiful area of Arlington, Virginia. Guests will find easy access to the local attractions as the hotel is located just two blocks from the Pentagon City Metro Stop on the Blue & Yellow Line.

A discounted rate of \$199 Single/Double has been extended to attendees.

Doubletree Hotel Crystal City

300 Army Navy Drive
Arlington, VA 22202-2891
Tel: 1-703-416-4100
Fax: 1-703-416-4126

Room Rate: \$199 Single/Double*
(Reference "PAG" and the meeting dates)

Check-in: 3:00 PM

Check-out: 12:00 PM

*For hotel reservations, please contact the Doubletree Crystal City at number listed above. **Refer to code PAG and the dates of the meeting (October 28-31, 2009) when calling.** For convenience on line, you may also use a special group booking website available at www.cancerandbonesociety.com under the travel and accommodations section. Take advantage of booking your room at the group rate and receiving your confirmation on line.

A credit card will be required for all hotel reservations. **All requests for accommodations must be received no later than September 29, 2009 or until the room block is sold out.** Reservations received after this date will be accepted based on space and rate availability.

For More Information

For more information about sponsorship, registration, program and special needs including dietary and accessibility, please contact The Paget Foundation at 212-509-5335.

For Program Updates and Registration

WWW.CANCERANDBONESOCIETY.ORG